Monograph Details
|
|
Endocrine System
> Diabetes
|
|
NOVOLOG |
| Manufacturer |
|
Novo Nordisk |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Insulin aspart (recombinant) 100 Units/mL; soln for SC inj, continuous subcutaneous insulin infusion (CSII), IV infusion; contains zinc, m-cresol. |
| Indications |
|
Diabetes. |
| Children |
|
<2yrs: not recommended. 2–4yrs: use SC inj only. ≥4yrs: may use SC inj or CSII: see literature. Onset approx ≤15 minutes, peak approx 1–3 hours, duration approx 3–5 hours. |
| Adults |
|
For SC inj, CSII, or IV infusion: see literature. Onset approx ≤15 minutes, peak approx 1–3 hours, duration approx 3–5 hours. |
| Contraindications |
|
During episodes of hypoglycemia. |
| Precautions |
|
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Potentiated by salicylates, MAOIs, alcohol, sulfa drugs, some ACE inhibitors, drugs that inhibit pancreatic function (eg, octreotide). Antagonized by corticosteroids, isoniazid, niacin, thiazides, phenothiazines, sympathomimetics. Variable effects with β-blockers, clonidine, lithium salts, alcohol. CSII: Do not mix with other insulins or diluent when pump is used. |
| Adverse Reactions |
|
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema. |
| How Supplied |
Vials (10mL)—1
FlexPen (3mL prefilled syringe)—1
PenFill (3mL cartridges)—1
NovoPen 3 (inj device, uses PenFill cartridges)—1
NovoLog NovoPen Junior (inj device, uses PenFill cartridges)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
